(PRECISION) A Phase II Study of the Optune System, Enhanced by Genomic Analysis to Identify the Genetic Signature of Response in the Treatment of Recurrent Glioblastoma Multiforme
The purpose of this research study is to collect information on how people respond to treatment with Optune and to see if their response to treatment relates to the genetic make-up of their tumor. Each person who participates in this study will have tumor tissue and blood tested for genetic sequencing, meaning that the exact genetic code of the tumor and blood will be identified.
- Disease: Brain tumor
- Disease type: Recurrent Glioblastoma Multiforme (GBM)
For additional information about eligibility criteria, please contact the study coordinatorDeborah Sampson
firstname.lastname@example.org (352) 273-9000
Can be done from home
KeywordsGlioblastoma multiforme, Tumor, Brain tumor - primary - adults
Principal InvestigatorDavid Tran, MD, PhD
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.